Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
57 participants
INTERVENTIONAL
2002-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Naltrexone Treatment for Alcoholism
NCT00000438
Use of Naltrexone in a Clinical Setting
NCT00000445
Naltrexone for Early Problem Drinkers
NCT00000455
The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion
NCT00667771
Targeted Naltrexone for Problem Drinkers
NCT00369408
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
naltrexone (Revia)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Abstinent from alcohol for a period of at least 3 days prior to beginning of study.
* Able to read English and complete study evaluations.
* Females who are postmenopausal, have had surgical sterilization, or use reliable means of birth control.
Exclusion Criteria
* Prior history of opioid dependence.
* Regular use of psychoactive drugs including anxiolytics and antidepressants.
* Prior treatment with naltrexone.
* Current use of disulfiram.
* Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current mania).
* Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac disease.
* Abstinent longer than 28 days prior to randomization.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
UConn Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIAAAKRA3510
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.